Physician profile
Lora Dillman
NPI 1396526992
$3,953.38
in general payments reported to CMS, 2019-2025
26 companies · $2,114 in 2025
The $2,114 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $35.83 · 2024: $1,804 · 2025: $2,114.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,933 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,933.16 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $713.60 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $560.73 | 2024-2025 | Airsupra, Farxiga |
| Abbvie INC. | $456.63 | 2024-2025 | |
| Lilly USA, LLC | $404.47 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $369.68 | 2023-2025 | |
| Pfizer INC. | $300.40 | 2024-2025 | |
| Amgen INC. | $150.49 | 2024-2025 | Evenity, Repatha, Otezla |
| Otsuka America Pharmaceutical, INC. | $113.44 | 2024-2025 | Rexulti |
| Axsome Therapeutics, INC. | $109.90 | 2024-2025 | Auvelity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $109.67 | 2024-2025 | Jardiance |
| Glaxosmithkline, LLC. | $88.06 | 2024-2025 | Trelegy Ellipta, Shingrix |
| Lundbeck LLC | $79.05 | 2024-2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $74.45 | 2024-2025 | Xifaxan |
| Astellas Pharma US INC | $63.07 | 2024-2025 | Veozah |
| Exact Sciences Corporation | $58.85 | 2024-2025 | Cologuard Collection Kit |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $47.93 | 2025 | Sapien 3 Ultra Resilia |
| Dexcom, INC. | $45.28 | 2025 | Dexcom G6 Transmitter |
| Phathom Pharmaceuticals, INC. | $36.42 | 2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $35.60 | 2024-2025 | Trintellix |
| Argenx US, INC. | $27.21 | 2025 | Vyvgart Hytrulo |
| Sumitomo Pharma America, INC. | $23.33 | 2025 | Gemtesa |
| Medtronic, INC. | $21.82 | 2024 | Interstim |
| Merck Sharp & Dohme LLC | $18.64 | 2025 | Enflonsia, Capvaxive, Gardasil 9 |
| Shield Therapeutics INC | $16.59 | 2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.49 | 2025 | Caplyta |
| Antares Pharma, INC. | $13.58 | 2025 | Xyosted |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lora Dillman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.